© Reuters Face Pharma to earn 89.5 million in foreign trade in 2022, 8.6% more
Madrid, March 29 (.) .- Faes Farma (BME:) achieved a net profit of 89.5 million euros in 2022, 8.6% more than last year, supported by strategic products and business internationalization, the company reported.
The pharmaceutical company’s turnover reached 439 million last year, up 10.1% year-on-year.
Face Pharma, which is present in 130 countries, has communicated with the Stock Market Regulator (CNMV) that the success of the Bilastin product will generate 110 million revenues (16% more than in 2021). Licenses are still pending in various markets.
The company saw double-digit growth in its related markets in Asia Pacific, Canada and Latam, and high-digit growth in Europe.
Only in the Iberian market, last year Fes Pharma entered 160 million in Spain and 31 million in Portugal, accounting for 47% of the total revenue of the pharmacy segment.
Regarding the industrial plan, the company aims to increase the production capacity by three to 100 million units. Specify a robotic warehouse with 12,800 positions and 10,000 square meters of manufacturing space of 20,000 square meters.
For 2023, Face Pharma predicts revenue growth of about 5.5% compared to 2022 and an EBITDA similar to last year.
He also expects revenue growth in the Latham market, around 20%, the stability of the animal nutrition and health business and the respiratory franchise (Ellipta) and the increase of the “health care” and consumer business in Spain.
However, the general situation of cost inflation and the need to strengthen the business structure in key geographies to support the growth plan.